Mounjaro Tablets UK: Do They Exist? (2026 Guide)

You have probably typed "Mounjaro tablets" into Google and found a wall of pharmacy pages that never quite answer the question. So here is the plain answer. If you are hoping to swap the weekly jab for a daily pill with the same name, there is something you need to know first.

There is no Mounjaro tablet. Mounjaro (tirzepatide) exists only as a once-weekly injection, and searching for the pill version has become one of the fastest-growing questions in UK weight loss. Our own analysis of search data found UK searches for "Mounjaro tablets" rose about 236% over the past year (DataForSEO search-volume data, July 2026), climbing from roughly 3,600 a month in mid-2025 to nearly 15,000 by summer 2026. People clearly want an oral option. The better news is that oral weight-loss medication has arrived in Britain this year, just not under the Mounjaro name.

Is there a Mounjaro tablet?

No. There is no tablet, capsule, or pill form of Mounjaro anywhere in the world, and none is licensed for sale in the UK. Eli Lilly, the company that makes it, confirms that tirzepatide is supplied only as an injectable medicine and is not available in an oral form.

Mounjaro is the brand name for tirzepatide. You take it as a once-weekly injection using a pre-filled pen, usually into the stomach, thigh, or upper arm. The dose starts low, at 2.5mg, and increases every four weeks or so under clinical guidance. If you want the detail on that, our Mounjaro dosage guide walks through the full titration schedule.

So if you come across a website selling "Mounjaro tablets" or "tirzepatide pills", treat that as a warning sign rather than a lucky find. It is not a legitimate product. Buying unlicensed medication from unverified sellers is one of the biggest risks with weight-loss treatment bought online: you have no idea what is actually in the box, at what dose, or made under what conditions. It is worth being blunt about that.

Why isn't Mounjaro available as a tablet?

This is not laziness on the manufacturer's part. It is chemistry.

Tirzepatide is a peptide, a chain of amino acids, and a fairly large one at that, with a molecular weight of around 4,800 daltons. Your digestive system is designed to break peptides down. That is what it does to the protein in your dinner. Swallow a peptide like tirzepatide and your stomach acid and enzymes would dismantle most of it long before it reached your bloodstream. As a rough rule, molecules much heavier than 500 daltons struggle to cross the gut wall intact, and tirzepatide is nearly ten times that.

Getting a peptide to survive the stomach takes clever formulation: absorption enhancers, protective coatings, strict rules about taking it on an empty stomach. It can be done, and it has been done for semaglutide, but it is difficult and the absorbed dose is small and variable.

What oral weight-loss medications can you actually get in the UK?

Here is where the news is better than most search results suggest. As of 2026, the UK finally has an oral GLP-1 licensed for weight loss, and a couple of other tablets sit nearby. None of them is Mounjaro, but they answer the underlying wish for a pill.

The point worth holding onto: an oral GLP-1 for weight loss now exists in Britain, but it contains semaglutide, the same drug family as Wegovy, not tirzepatide. For a wider view of the injectable and oral options side by side, our guide to weight loss medication in the UK covers the full menu.

The Wegovy pill: the first oral weight-loss GLP-1 in the UK

This is the headline that has changed the picture. In June 2026, the medicines regulator, the MHRA, approved a 25mg semaglutide tablet for weight management, making it the first daily oral GLP-1 for weight loss licensed in Europe. People often call it the Wegovy pill, because it uses the same active ingredient as the Wegovy injection.

It is a daily tablet rather than a weekly jab, and the results are respectable. In the OASIS 4 trial that supported approval, adults taking the 25mg dose lost around 16.6% of their body weight over 64 weeks when they stayed on treatment, and roughly three in ten lost 20% or more. Even on the more conservative measure that counts everyone regardless of whether they kept taking it, average weight loss was about 13.6%, against roughly 2.4% for placebo.

Side effects mirror the rest of the GLP-1 family. In the OASIS 4 trial, about three-quarters of people on the tablet reported gastrointestinal effects such as nausea, vomiting, or diarrhoea, though most were mild to moderate and settled with time. That pattern will feel familiar to anyone who has read up on the injections.

There is a catch that matters day to day. Oral semaglutide has to be taken on an empty stomach with a small sip of plain water, then you wait around 30 minutes before eating, drinking, or taking anything else. Miss that window and absorption drops. For some people a weekly injection with no food rules is easier to live with than a daily tablet that demands a strict morning routine. Our GLP-1 tablets guide goes deeper on how the pill works and who it suits.

Orforglipron: the oral pill that isn't a peptide

The other name you will see in the headlines is orforglipron, sold in the US as Foundayo. In April 2026 the US regulator approved it as the first GLP-1 pill for weight loss you can take any time of day, with or without food. That flexibility is the big selling point, and it comes from orforglipron being a small molecule rather than a peptide, so it shrugs off stomach acid in a way tirzepatide never could.

In its ATTAIN-1 trial, the highest dose produced about 12.4% weight loss over 72 weeks, compared with under 1% for placebo. That is a meaningful result for a pill, though a little below what the strongest injections deliver.

Two honest caveats. First, orforglipron is not licensed in the UK yet, so you cannot get it here through a legitimate route as of mid-2026. Second, it is a separate drug, not an oral Mounjaro. If you are curious, we cover it in detail in our orforglipron guide.

Will there ever be a Mounjaro tablet?

Probably not in the form people imagine. Because tirzepatide is such a large peptide, Eli Lilly has chosen to invest in orforglipron instead of trying to squeeze tirzepatide into a pill. There is no oral tirzepatide product in late-stage trials and no filing date on the horizon. Anyone promising "Mounjaro tablets coming soon" with a specific date is guessing.

That does not mean oral options are standing still. The opposite is true. Between the newly approved semaglutide tablet and orforglipron waiting in the wings, the oral GLP-1 space is moving quickly. It is just that the pills arriving are new medicines with their own names, not a tablet version of the injection you searched for.

Tablet versus injection: do you lose the same weight?

Not quite, and this is where it helps to be realistic rather than swept up in the novelty of a pill.

Injections still lead on average weight loss. In the SURMOUNT-1 trial, the highest dose of Mounjaro produced average weight loss of around 21% over 72 weeks, among the strongest results seen for any weight-loss medicine. The 25mg semaglutide tablet lands closer to the mid-teens in percentage terms, and orforglipron a little below that. So the current trade-off is broadly: the pen tends to deliver more weight loss, while a tablet removes the needle and, for orforglipron at least, the food-timing rules.

For a broader comparison of the jabs available here, including how they differ in mechanism and side effects, see our guide to the best weight loss injections in the UK.

What to do if you want Mounjaro now

If it is Mounjaro specifically you are after, the route is the same as it has always been: the weekly injection, prescribed after a proper medical assessment.

In the UK you can get tirzepatide on the NHS for obesity, following NICE guidance and the NHS weight-management pathway, though the rollout is staged and eligibility is tightly defined, so many people access it privately through a regulated online pharmacy instead. Either way, a clinician checks your BMI, health history, and any other medications before anything is prescribed.

The injection itself puts a lot of people off before they have tried it, and that is understandable. In practice the needle is very short and fine, and most people find it far more manageable than they expected. If that is your worry, our guide on where and how to inject Mounjaro shows exactly what is involved.

This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional before starting any treatment.